Cash flow hedge loss to be reclassified

[Table of Contents](#i8e6404ebd98d416daa7f88f48159b601_7)EDWARDS LIFESCIENCES CORPORATIONNOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)12.    DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES (Continued)

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  | Location and Amount of Gain or (Loss) Recognized in Income on Fair Value and Cash Flow Hedging Relationships |
|   | Twelve Months Ended December 31, 2020 |
|   | Cost of sales |  | Selling, general, and administrative expenses |  |  |  | Other Income, net |
|  |  |  |  |
| Total amounts of income and expense line items shown in the consolidated statements of operations in which the effects of fair value or cash flow hedges are recorded | $ | (1,080.6) |  |  | $ | (1,228.4) |  |  |  |  | $ | 11.5  |  |
| The effects of fair value and cash flow hedging: |  |  |  |  |  |  |  |
| Gain (loss) on fair value hedging relationships: |  |  |  |  |  |  |  |
| Foreign currency contracts: |  |  |  |  |  |  |  |
| Hedged items | —  |  |  | —  |  |  |  |  | 4.8  |  |
| Derivatives designated as hedging instruments | —  |  |  | —  |  |  |  |  | (4.8) |  |
| Amount excluded from effectiveness testing recognized in earnings based on an amortization approach | —  |  |  | —  |  |  |  |  | 3.4  |  |
| Gain (loss) on cash flow hedging relationships: |  |  |  |  |  |  |  |
| Foreign currency contracts: |  |  |  |  |  |  |  |
| Amount of gain (loss) reclassified from accumulated OCI into income | 18.4  |  |  | 2.2  |  |  |  |  | —  |  |

The Company expects that during 2022 it will reclassify to earnings a $7.8 million gain currently recorded in "Accumulated Other Comprehensive Loss." For the years ended December 31, 2021, 2020, and 2019, the Company did not record any gains or losses due to hedge ineffectiveness.  
70
